Advancing AVR: New Guidelines and the Heart Team's Vital Role in Lifetime Management
-
16m 2s
-
9m 22s
Dr Chris Cook introduces the faculty and outlines the session’s focus on updated ESC/EACTS guidelines, valve durability, and personalised AVR strategies. Prof Augusto D’Onofrio reviews the 2025 guideline updates for aortic stenosis, including earlier intervention for select asymptomatic patients, management of bicuspid valves, and age-based considerations for TAVI versus SAVR. The chapter emphasises lifetime management, valve durability, and the heart team’s pivotal role in optimising patient outcomes.
Aortic valve replacement (AVR) continues to evolve, with new evidence, technologies and guidelines shaping best practice for lifetime management. This recording of the live webinar brings together leading experts to review the valvular heart disease 2025 ESC/EACTS guidelines, explore the latest data – including on asymptomatic severe AS – and highlight the role of RESILIA tissue technology and the SAPIEN 3 Ultra RESILIA valve in enhancing durability and long-term outcomes.
In these on-demand videos, moderator Dr Chris Cook (Mid and South Essex NHS Foundation Trust, Basildon, UK) is joined by leading faculty, Dr Pilar Jimenez-Quevedo (Hospital Clínico San Carlos, Madrid, ES), Dr Clare Appleby (Liverpool Heart and Chest Hospital, Liverpool, UK), Prof Augusto D'Onofrio (University of Rome "Tor Vergata", Rome, IT) and Dr Marwa Daghem (Liverpool Heart and Chest Hospital, Liverpool, UK) for real-world case discussions, guideline reviews and to provide expert perspectives to support optimal patient outcomes.
Viewers will gain practical insights on patient selection, treatment strategies and managing complex scenarios. Designed for interventional cardiologists and other associated healthcare professionals, these videos provide clear, actionable takeaways to optimise decision-making and strengthen collaboration within the heart team.
Watch this session to:
- Gain insights into the latest updates in the ESC / EACTS guidelines
- Discover how RESILIA tissue technology enhance valve durability and long-term outcomes
- Discuss personalised AVR treatment strategy through real world cases
This session will provide particular insight for:
- Interventional Cardiologists
- Non-invasive Cardiologists
- Cardiothoracic Surgeons
- Healthcare Professional in Training
More from this programme
Part 1
Welcome and ESC/EACTS 2025 Guidelines – What’s New and What Is the Expected Impact?
Dr Chris Cook introduces the faculty and outlines the session’s focus on updated ESC/EACTS guidelines, valve durability, and personalised AVR strategies. Prof Augusto D’Onofrio reviews the 2025 guideline updates for aortic stenosis, including earlier intervention for select asymptomatic patients, management of bicuspid valves, and age-based considerations for TAVI versus SAVR. The chapter emphasises lifetime management, valve durability, and the heart team’s pivotal role in optimising patient outcomes.
Part 2
Panel Discussion – Guideline Changes and Insights from Early TAVR
The panel reviews the evidence behind earlier intervention in asymptomatic severe aortic stenosis, centred on the EARLY TAVR trial. Dr Claire Appleby highlights its findings showing reduced hospitalisations with early TAVR, while Dr Pilar Jimenez-Quevedo and Prof Augusto D’Onofrio discuss crossover effects and differences between surgical and transcatheter data. Dr Marwa Daghem emphasises the need for careful symptom assessment and proactive, heart-team-led management as the field moves toward earlier treatment strategies.
Part 3
The RESILIA Tissue Technology & Surgical Experience
Prof Augusto D’Onofrio outlines the evolution of surgical bioprostheses and the development of RESILIA tissue technology, engineered to reduce calcification and extend valve durability. He shares long-term and real-world data showing excellent haemodynamic performance and minimal structural valve deterioration. The RESILIA valve is presented as a proven, valve-in-valve–ready option with strong results across age groups, supporting durable surgical solutions within lifetime management strategies for aortic valve replacement.
Part 4
SAPIEN 3 Ultra RESILIA Valve in Practice & Clinical Impact
Dr Pilar Jimenez-Quevedo reviews the SAPIEN 3 Ultra RESILIA valve, highlighting its calcification-resistant tissue technology and strong early outcomes. Registry data show lower gradients, reduced paravalvular leak, and improved safety versus previous SAPIEN and self-expanding valves. A real-world bicuspid stenosis case illustrates precise implantation and excellent haemodynamics, confirming the valve’s performance and durability in complex anatomies.
Part 5
Case 1 Presentation: Patient With Small Annuli (and Bicuspid) in Women, and Panel Discussion
Dr Pilar Jimenez-Quevedo presents a 77-year-old woman with severe bicuspid aortic stenosis and a small annulus, treated with the SAPIEN 3 Ultra RESILIA valve. Careful CT planning, pre-dilatation and precise deployment achieved excellent haemodynamics and no paravalvular leak. The case underscores the value of tailored procedural strategy and heart team collaboration in managing complex bicuspid anatomies in women with small annuli.
Part 6
Case 2 Presentation: Re-do AVR Case, and Session Summary
Dr Marwa Daghem presents a 64-year-old man with prior surgical AVR and recurrent stenosis, showcasing lifetime management in aortic valve disease. Following the heart team's assessment, the patient underwent successful valve-in-valve TAVI with a SAPIEN 3 Ultra RESILIA valve, avoiding high-risk re-operation. The case emphasised procedural planning in complex anatomy and the importance of shared decision making. The session concludes by reaffirming the heart team’s vital role in long-term AVR care.
Faculty Biographies
Augusto D’Onofrio
Prof Augusto D’Onofrio is a leading Italian cardiac surgeon based in Rome, Italy. He earned his medical degree from the Catholic University of Rome in 2000 and completed his residency in cardiac surgery at the University of Verona in 2005, later obtaining a PhD in Cardiovascular Sciences from the University of Padova in 2013. Prof D’Onofrio has held senior surgical roles across Italy, including at San Bortolo Hospital in Vicenza and the University Hospital of Padova, and currently serves as Associate Professor of Cardiac Surgery and interim Chief of the Division of Cardiac Surgery at the University of Rome "Tor Vergata."
His clinical and research work focuses on complex aortic surgery, transcatheter aortic valve implantation (TAVI), and minimally invasive cardiac procedures. Widely published with over 100 peer-reviewed papers, Prof D’Onofrio is an active member of major European and Italian cardiac surgery societies and is a regular speaker at international conferences.
Christopher M Cook
Dr Christopher Cook is an interventional cardiologist at the Essex Cardiothoracis Centre, Basildon, UK. He has served as a MRC Clinical Research Fellow at the National Heart and Lung Institute, Imperial College London, with primary research interests are in coronary physiology and invasive haemodynamics. Dr Cook studied Medicine at UCL, UK, graduating with Distinction and multiple prizes including the prestigious Proxime Accessit Gold Medal Medicine (London) in 2009. He was the winner of the inaugural PCR’s Got Talent award at EuroPCR2015 and he has since been a EuroPCR Programme Committee member.
Clare Appleby
Dr Clare Appleby is an interventional cardiologist at Liverpool Heart and Chest Hospital, Liverpool, UK. Trained in Wythenshawe and Blackpool, UK, Dr Appleby was awarded a BCIS Interventional Fellowship in Toronto, Canada. Her research interests include gene therapy for atherosclerosis and PCI outcomes. Dr Appleby has served as PI for several multi-centre PCI and TAVI trials. She has served as Honorary Secretary of the British Cardiovascular Intervention Society.
Marwa Daghem
Dr Marwa Daghem is an interventional cardiologist based at Liverpool Heart and Chest Hospital, Liverpool, UK. Dr Daghem’s key research and clinical focus includes TAVI and congenital heart disease.
Pilar Jimenez-Quevedo
Interventional Cardiologist
Dr Pilar Jiménez-Quevedo is a specialist in interventional cardiology based in Madrid, Spain. Dr Jiménez-Quevedo earned her Degree in Medicine from the University of Navarra, a masters in Interventional Cardiology and a Doctor Cum Laude in Medicine and Surgery from the Complutense University of Madrid.
From 2005 to 2006, she worked as a Research Fellow at Stem Cell Center at Texas Heart Institute, Houston, US. Dr Jiménez-Quevedo has participated in pioneering surgical intervention, including the first implantation of a transcatheter self-expanding mitral prosthesis with minimally-invasive surgery in Spain. Since 1998, Dr Jiménez-Quevedo has been developing healthcare and research activities in the Hemodynamics and Interventional Cardiology Unit of the San Carlos University Hospital, Madrid. She is a tutor for cardiology residents, a fellow of the European Society of Cardiology and was previously a member of the board of directors of the Interventional…